HXXB Idera Pharmaceuticals Inc.

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Idera Pharmaceuticals, Inc. (IDRA) on Behalf of Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--

Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) stockholders concerning the proposed merger of the company with BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX).

Our investigation concerns whether Idera’s board of directors failed to adequately shop the company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with BioCryst. Under the terms of the agreement, Idera stockholders will receive 0.20 shares of the combined company stock for each share of Idera common stock they own. On a proforma, fully diluted basis, Idera stockholders will own 48.4 percent of the combined company.

If you own Idera shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation of Idera Pharmaceuticals, Inc., please go to http://www.bespc.com/idera. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

EN
22/01/2018

Underlying

HXXBIdera Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Idera Pharmaceuticals Inc.

 PRESS RELEASE
Free
HXXB Idera Pharmaceu...

Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Prov...

Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA), a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today annou...

January 17, 2023 1 EN
 PRESS RELEASE
Free
HXXB Idera Pharmaceu...

Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and...

Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. “We are pleased to have completed the merger of Idera and Aceragen at the end of the third quarter, better enabling us to deliver important therapies for people living with rare diseases,” stated John Taylor, Idera’s Chief Executi...

November 14, 2022 1 EN
 PRESS RELEASE
Free
HXXB Idera Pharmaceu...

Idera Pharmaceuticals Acquires Aceragen

Idera Pharmaceuticals Acquires Aceragen Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today announced it has completed the acquisition of Aceragen, Inc. (“Aceragen”), a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there ...

September 28, 2022 1 EN
 PRESS RELEASE
Free
HXXB Idera Pharmaceu...

Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results

Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022. Second Quarter Financial Results Our cash position as of June 30, 2022 was $24.5 million. Based on our current operating plan, we anticipate that our current cash and cash equivalents will fund our operations through the one-year period subsequent to the August 9, 2022 filing date of the Quar...

August 9, 2022 1 EN
 PRESS RELEASE
Free
HXXB Idera Pharmaceu...

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponso...

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC – Enrollment Stopped Early for Efficacy – EXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Idera’s synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early. INTRIM 1 is a randomized, do...

May 17, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch